Abstract A24: The dual PI3K δ/γ inhibitor, RP6530, in combination with ibrutinib or fludarabine, synergistically enhances cytotoxicity in primary CLL cells in vitro.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Vakkalanka, S; Penmetsa, KV; Chasse, D; Chen, Y; Viswanadha, S; Friedman, DR; Weinberg, JB

Published Date

  • September 1, 2015

Published In

  • Drug Discovery

Published By

Digital Object Identifier (DOI)

  • 10.1158/1557-3265.hemmal14-a24

Conference Name

  • Abstracts: AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; September 20-23, 2014; Philadelphia, PA